GlobeNewswire Inc | Feb 18, 2021 07:30AM EST

February 18, 2021

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Digital RAS-Targeted Drug Discovery Summit being held February 23-25, 2021. Steve Kelsey, M.D., president, research and development, will be a featured speaker during the virtual event and will provide a scientific update on the companys first-in-class RAS(ON) Inhibitor programs.

Revolution Medicines recently announced the entry of two RAS(ON) Inhibitor programs into IND-enabling development: RMC-6291, a potent, oral and selective tri-complex inhibitor of KRASG12C(ON); and RMC-6236 a potent, oral and RAS-selective tri-complex KRASMULTI(ON) inhibitor.

Details of Revolution Medicines participation in the RAS-Targeted Drug Development Summit are as follows:

Presentation:

Title: Drugging the RAS(ON) Form of Diverse Oncogenic RAS MutationsPresenter: Steve Kelsey, M.D., president, research and developmentDate: Thursday, February 25, 2021Time: 10:30 a.m. Eastern

Panel Discussion:

Title: Mechanisms of Resistance for Combination TherapiesParticipant: Steve Kelsey, M.D., president, research and developmentDate: Thursday, February 25, 2021Time: 11:00 a.m. Eastern

Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdiscovery.com/.

Revolution Medicines also today announced that the company will participate in three upcoming investor conferences. Details of these events are as follows:

-- 10th Annual SVB Leerink Global Healthcare ConferenceFireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairmanConference date: February 22-26, 2021Fireside chat time: 1:40 2:10 p.m. Eastern on February 25, 2021Format: Virtual conference; webcast available

-- 41st Annual Cowen Healthcare ConferenceFireside chat with Mark A. Goldsmith, M.D., Ph.D., CEO and chairmanConference dates: March 1-4, 2021Fireside chat time: 10:20 10:50 a.m. Eastern on March 3, 2021Format: Virtual conference; webcast available

-- HC Wainwright Global Life Science ConferenceCorporate presentation delivered by Mark A. Goldsmith, M.D., Ph.D., CEO and chairmanConference dates: March 9-10, 2021Presentation time: 7:00 a.m. Eastern on March 9, 2021Format: Virtual conference; webcast available

To access the live webcasts of the fireside chats and corporate presentation at these investor conferences, please visit the Events & Presentations page within the Investors section of Revolution Medicines website at https://ir.revmed.com/events-and-presentations. Additionally, replays of the webcasts will be available on the Events & Presentations page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291 and RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Revolution Medicines development plans and timelines and the companys ability to advance its portfolio and R&D pipeline, including its RAS(ON) Inhibitor programs that are in IND-enabling development. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the companys programs early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the companys ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the companys capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines Registration Statement on Form S-1 initially filed with the Securities and Exchange Commission on February 1, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Contacts:

For Investors:Vida Strategic PartnersStephanie Diaz415-675-7401sdiaz@vidasp.com

For Media:Vida Strategic PartnersTim Brons415-675-7402tbrons@vidasp.com